Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Aishwarya who wrote (399)	3/31/1998 9:01:00 PM
From: Y2k_fan	Respond to of 2887

What I learned from the past year. Unless the fundamental of your investment changes, keep faith in your investment. Long term investors are always the winner. My portfolio has increased by > 100% this year, and it's only end of March. It could have been much higher if I don't switch too often. Go ABMI!

To: Aishwarya who wrote (399)	4/1/1998 12:34:00 AM
From: R.C.L.	Read Replies (1) \| Respond to of 2887

More good news sri-- Tuesday March 31, 8:18 pm Eastern Time Stents found beneficial after balloon angioplasty By Mike Cooper ATLANTA, March 31 (Reuters) - Implanting a stent, a coil of steel mesh, after balloon angioplasty can further improve blood flow in patients with blocked coronary arteries, researchers said on Tuesday. Patients who received a stent, a steel mesh coil which can keep arteries open, after balloon angioplasty were less likely to need further treatment for the same blood vessel than those who received the balloon angioplasty alone, said Dr. Christopher Buller of the University of British Columbia in Vancouver. Balloon angioplasty involves the use of a balloon at the tip of a catheter to open blocked blood vessels. A stent can be put in place after the blockage has been cleared. A study of almost 400 patients at 18 centers in four countries found implanting a stent after balloon angioplasty reduced by 44 percent the risk the treatment would fail within six months, Buller told a meeting of the American College of Cardiology. Buller said the findings from the Total Occlusion Study of Canada (TOSCA) demonstrate the value of stenting in patients with chronic, totally occluded coronary arteries. He said patients who received the stent had better blood flow. Researchers said it is more difficult to open a totally blocked artery than a partially-blocked artery. It is also more difficult to keep the artery open after a blockage has been cleared. Preliminary results of another study of the value of stents after balloon angioplasty were also presented at the meeting. However, Dr. Cindy Grines of William Beaumont Hospital in Royal Oak, Michigan, said it was too early to reach conclusions in the study of 900 patients who had suffered heart attacks. Doctors are increasingly using stents coated with drugs such as heparin, which reduces platelet deposits on the stent. A study of 2,400 patients who underwent coronary stenting or balloon angioplasty found that using the anti-platelet antibody abciximab reduced the rate of death or heart attack by 54 percent. ''Since stents already were known to stabilize the coronary arteries, it was unclear whether the addition of anti-platelet antibodies would be important,'' said Dr. Eric Topol of the Cleveland Clinic Department of Cardiology, who chaired the study. ''The magnitude of the benefit is quite remarkable, especially superimposed on stenting, which up until now was considered state-of-the-art therapy.''